Dallas, Texas
CNS medication trials in Dallas, TX
36 CNS medication studies are recruiting participants at sites in Dallas as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Dallas at a glance
- 36 studies are recruiting at a site in Dallas.
- By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (1), Phase 2 (6), Phase 3 (22), Phase 4 (4), No phase (1). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (31), university, hospital or other (4), government (1).
- By research area: Depression (10), Migraine (10), Parkinson's Disease (8), Multiple Sclerosis (4), Epilepsy (3), Schizophrenia (1).
- Most recent update to one of these records: November 17, 2026.
Depression studies recruiting in Dallas
Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Seaport Therapeutics
- Study site
- Seaport Investigator Site
- Registry record
- NCT07065240 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Future Search Trials of Dallas
- Registry record
- NCT07573176 · updated
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Neurocrine Biosciences
- Study site
- Neurocrine Clinical Site
- Registry record
- NCT06966401 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT07553637 · updated
ALTO-100 in Bipolar Disorder With Depression (BD-D)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT06656416 · updated
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07484217 · updated
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Relaro Medical Trials /ID# 227156
- Registry record
- NCT04777357 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Dallas, TX on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Texas Oncology - DFW ( Site 8103) · UT Southwestern Medical Center ( Site 0190)
- Registry record
- NCT06623422 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - DFW ( Site 8007)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Texas Oncology - DFW ( Site 8009) · UT Southwestern ( Site 0092)
- Registry record
- NCT06966700 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Texas Neurology PA
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Neurology Consultants of Dallas PA
- Registry record
- NCT06680830 · updated
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Parkland Health and Hospital System ( Site 0069) · Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) · UT Southwestern Medical Center ( Site 0050)
- Registry record
- NCT06312176 · updated
Motor Network Physiology
- No phase
- Ages 18 to 89
- All sexes
- Sponsor
- University of Texas Southwestern Medical Center
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT04957095 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Dallas, TX on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Dallas
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT03816345 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Univ of Texas Southwest Med Center
- Registry record
- NCT06846281 · updated
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Carum Research
- Registry record
- NCT07225504 · updated
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- Oculis
- Study site
- UT Southwestern Medical Center (Ophthalmology CRU)
- Registry record
- NCT07623668 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Dallas, TX on ClinicalTrials.gov.
Epilepsy studies recruiting in Dallas
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
- Phase 3
- Ages 2 to 55
- All sexes
- Sponsor
- Epygenix
- Study site
- Children's Health Specialty Center
- Registry record
- NCT05066217 · updated
Pharmacological Modulation of Brain Oscillations in Memory Processing
- Early Phase 1
- Ages 18 to 55
- All sexes
- Sponsor
- University of Texas Southwestern Medical Center
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT05594017 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Dallas, TX on ClinicalTrials.gov.
Migraine studies recruiting in Dallas
Study of EVO756 in Adults With Migraine
- Phase 2
- Ages 18 to 64
- All sexes
- Sponsor
- Evommune, Inc.
- Study site
- FutureSearch Trials of Dallas
- Registry record
- NCT07616128 · updated
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Velocity Clinical Research, Dallas
- Registry record
- NCT07816367 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- FutureSearch Trials of Dallas, LP
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- FutureSearch Trials of Dallas, LP
- Registry record
- NCT07674654 · updated
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study site
- FutureSearch Trials of Dallas, LLC
- Registry record
- NCT04649242 · updated
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study site
- Alina Clinical Trials, LLC.
- Registry record
- NCT05156398 · updated
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- FutureSearch Trials of Dallas
- Registry record
- NCT07609914 · updated
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- FutureSearch Trials of Dallas
- Registry record
- NCT07729462 · updated
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- AbbVie
- Study sites
- Cedar Health Research /ID# 228003 · Relaro Medical Trials /ID# 239642
- Registry record
- NCT05125302 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Dallas, TX on ClinicalTrials.gov.
Ask about studies near Dallas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
147 studies recruiting across 48 cities.
Houston
66 studies recruiting.
Austin
52 studies recruiting.
San Antonio
25 studies recruiting.
Richardson
24 studies recruiting.
DeSoto
23 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections